NASDAQ:PODDInsulet Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Insulet Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $164.92 -2.12 (-1.27 %) (As of 04/5/2020 04:00 PM ET) Add Compare Share Today's Range$162.27Now: $164.92▼$171.1050-Day Range$130.01MA: $178.14▼$216.4452-Week Range$80.43Now: $164.92▼$219.85Volume447,466 shsAverage Volume781,233 shsMarket Capitalization$10.37 billionP/E Ratio916.22Dividend YieldN/ABeta0.86 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod. It sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, Israel, and internationally. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.Read More Beat the Market (BTM) Rank™ 2.2 Analyst's Opinion Consensus RatingInsulet has received a consensus rating of Hold. The company's average rating score is 2.45, and is based on 10 buy ratings, 9 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $173.00, Insulet has a potential upside of 4.9% from its current price of $164.92.Amount of Analyst CoverageInsulet has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.7 Community Rank Outperform VotesInsulet has received 646 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInsulet has received 559 “underperform” votes. (Add your “underperform” vote.)Community SentimentInsulet has received 53.61% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Insulet and other stocks. Vote “Outperform” if you believe PODD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PODD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInsulet does not currently pay a dividend.Dividend GrowthInsulet does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,665,195.00 in company stock.Percentage Held by InsidersOnly 3.50% of the stock of Insulet is held by insiders. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Insulet are expected to grow by 182.69% in the coming year, from $0.52 to $1.47 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insulet is 916.22, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 11.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Insulet is 916.22, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 17.99.Price to Book Value per Share RatioInsulet has a P/B Ratio of 134.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.36 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:PODD Previous Symbol CUSIP45784P10 CIK1145197 Webhttp://www.insulet.com/ Phone978-600-7000Debt Debt-to-Equity Ratio11.70 Current Ratio3.75 Quick Ratio3.11Price-To-Earnings Trailing P/E Ratio916.22 Forward P/E Ratio317.15 P/E GrowthN/A Sales & Book Value Annual Sales$738.20 million Price / Sales14.04 Cash Flow$0.63 per share Price / Cash Flow261.43 Book Value$1.23 per share Price / Book134.08Profitability EPS (Most Recent Fiscal Year)$0.19 Net Income$11.60 million Net Margins1.58% Return on Equity9.56% Return on Assets1.54%Miscellaneous Employees1,350 Outstanding Shares62,860,000Market Cap$10.37 billion Next Earnings Date5/7/2020 (Estimated) OptionableOptionable Receive PODD News and Ratings via Email Sign-up to receive the latest news and ratings for PODD and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PODD Rates by TradingView Insulet (NASDAQ:PODD) Frequently Asked Questions How has Insulet's stock been impacted by COVID-19 (Coronavirus)? Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PODD stock has decreased by 4.2% and is now trading at $164.92. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Insulet? 20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 9 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Insulet. When is Insulet's next earnings date? Insulet is scheduled to release its next quarterly earnings announcement on Thursday, May 7th 2020. View our earnings forecast for Insulet. How were Insulet's earnings last quarter? Insulet Co. (NASDAQ:PODD) released its quarterly earnings results on Tuesday, February, 25th. The medical instruments supplier reported $0.08 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.09 by $0.01. The medical instruments supplier earned $209.40 million during the quarter, compared to analysts' expectations of $197.79 million. Insulet had a return on equity of 9.56% and a net margin of 1.58%. View Insulet's earnings history. What guidance has Insulet issued on next quarter's earnings? Insulet updated its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $841.548-871.076 million, compared to the consensus revenue estimate of $879.83 million. What price target have analysts set for PODD? 20 brokerages have issued twelve-month target prices for Insulet's stock. Their forecasts range from $100.00 to $215.00. On average, they expect Insulet's share price to reach $173.00 in the next twelve months. This suggests a possible upside of 4.9% from the stock's current price. View analysts' price targets for Insulet. Has Insulet been receiving favorable news coverage? News headlines about PODD stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insulet earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutInsulet. Who are some of Insulet's key competitors? Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Stryker (SYK), Intuitive Surgical (ISRG), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), DexCom (DXCM), ResMed (RMD), IDEXX Laboratories (IDXX), Teleflex (TFX), Steris (STE), Masimo (MASI) and Hologic (HOLX). What other stocks do shareholders of Insulet own? Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include Alibaba Group (BABA), NVIDIA (NVDA), DexCom (DXCM), Netflix (NFLX), salesforce.com (CRM), Roku (ROKU), Tandem Diabetes Care (TNDM), Veeva Systems (VEEV), Adobe (ADBE) and Splunk (SPLK). Who are Insulet's key executives? Insulet's management team includes the following people: Ms. Shacey Petrovic, Pres, CEO & Director (Age 45)Mr. Charles Alpuche, Exec. VP & COO (Age 59)Mr. Bret Christensen, Exec. VP & Chief Commercial Officer (Age 47)Mr. Patrick J. Sullivan, Consultant (Age 67)Mr. Michael L. Levitz, Advisor (Age 45) What is Insulet's stock symbol? Insulet trades on the NASDAQ under the ticker symbol "PODD." How do I buy shares of Insulet? Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Insulet's stock price today? One share of PODD stock can currently be purchased for approximately $164.92. How big of a company is Insulet? Insulet has a market capitalization of $10.37 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe. View additional information about Insulet. What is Insulet's official website? The official website for Insulet is http://www.insulet.com/. How can I contact Insulet? Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected] This page was last updated on 4/5/2020 by MarketBeat.com StaffFeatured Article: Most Active Stocks: Dollar Volume vs Share Volume
